The partnership with ProteoNic Biosciences is likely to enhance Ginkgo Bioworks' offerings in cell programming and biosecurity, making its platform more attractive to customers seeking advanced vector technologies for protein production and gene therapy. This strategic alliance could potentially lead to increased customer interest and adoption of Ginkgo's services, positively impacting its stock price in the short term.